Lipidomic profiling of human serum enables detection of pancreatic cancer

Denise Wolrab; Robert Jirásko; Eva Cífková; Marcus Höring; Ding Mei; Michaela Chocholoušková; Ondřej Peterka; Jakub Idkowiak; Tereza Hrnčiarová; Ladislav Kuchař; Robert Ahrends; Radana Brumarová; David Friedecký; Gabriel Vivo-Truyols; Pavel Škrha; Jan Škrha; Radek Kučera; Bohuslav Melichar; Gerhard Liebisch; Ralph Burkhardt; Markus R. Wenk; Amaury Cazenave-Gassiot; Petr Karásek; Ivo Novotný; Kristína Greplová; Roman Hrstka; Michal Holčapek

doi:10.1038/s41467-021-27765-9

Lipidomic profiling of human serum enables detection of pancreatic cancer

Denise Wolrab, Robert Jirásko, Eva Cífková, Marcus Höring, Ding Mei, Michaela Chocholoušková, Ondřej Peterka, Jakub Idkowiak, Tereza Hrnčiarová, Ladislav Kuchař, Robert Ahrends, Radana Brumarová, David Friedecký, Gabriel Vivo-Truyols, Pavel Škrha, Jan Škrha, Radek Kučera, Bohuslav Melichar, Gerhard Liebisch, Ralph BurkhardtMarkus R. Wenk, Amaury Cazenave-Gassiot, Petr Karásek, Ivo Novotný, Kristína Greplová, Roman Hrstka, Michal Holčapek^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

102 Citations (Scopus)

Abstract

Pancreatic cancer has the worst prognosis among all cancers. Cancer screening of body fluids may improve the survival time prognosis of patients, who are often diagnosed too late at an incurable stage. Several studies report the dysregulation of lipid metabolism in tumor cells, suggesting that changes in the blood lipidome may accompany tumor growth. Here we show that the comprehensive mass spectrometric determination of a wide range of serum lipids reveals statistically significant differences between pancreatic cancer patients and healthy controls, as visualized by multivariate data analysis. Three phases of biomarker discovery research (discovery, qualification, and verification) are applied for 830 samples in total, which shows the dysregulation of some very long chain sphingomyelins, ceramides, and (lyso)phosphatidylcholines. The sensitivity and specificity to diagnose pancreatic cancer are over 90%, which outperforms CA 19-9, especially at an early stage, and is comparable to established diagnostic imaging methods. Furthermore, selected lipid species indicate a potential as prognostic biomarkers.

Original language	English
Article number	124
Journal	Nature Communications
Volume	13
Issue number	1
DOIs	https://doi.org/10.1038/s41467-021-27765-9
Publication status	Published - Dec 2022
Externally published	Yes

Access to Document

10.1038/s41467-021-27765-9

Cite this

Wolrab, D., Jirásko, R., Cífková, E., Höring, M., Mei, D., Chocholoušková, M., Peterka, O., Idkowiak, J., Hrnčiarová, T., Kuchař, L., Ahrends, R., Brumarová, R., Friedecký, D., Vivo-Truyols, G., Škrha, P., Škrha, J., Kučera, R., Melichar, B., Liebisch, G., ... Holčapek, M. (2022). Lipidomic profiling of human serum enables detection of pancreatic cancer. Nature Communications, 13(1), Article 124. https://doi.org/10.1038/s41467-021-27765-9

@article{9b314d49ab4d4354b6dbef05c3c32f35,

title = "Lipidomic profiling of human serum enables detection of pancreatic cancer",

abstract = "Pancreatic cancer has the worst prognosis among all cancers. Cancer screening of body fluids may improve the survival time prognosis of patients, who are often diagnosed too late at an incurable stage. Several studies report the dysregulation of lipid metabolism in tumor cells, suggesting that changes in the blood lipidome may accompany tumor growth. Here we show that the comprehensive mass spectrometric determination of a wide range of serum lipids reveals statistically significant differences between pancreatic cancer patients and healthy controls, as visualized by multivariate data analysis. Three phases of biomarker discovery research (discovery, qualification, and verification) are applied for 830 samples in total, which shows the dysregulation of some very long chain sphingomyelins, ceramides, and (lyso)phosphatidylcholines. The sensitivity and specificity to diagnose pancreatic cancer are over 90%, which outperforms CA 19-9, especially at an early stage, and is comparable to established diagnostic imaging methods. Furthermore, selected lipid species indicate a potential as prognostic biomarkers.",

author = "Denise Wolrab and Robert Jir{\'a}sko and Eva C{\'i}fkov{\'a} and Marcus H{\"o}ring and Ding Mei and Michaela Chocholou{\v s}kov{\'a} and Ond{\v r}ej Peterka and Jakub Idkowiak and Tereza Hrn{\v c}iarov{\'a} and Ladislav Kucha{\v r} and Robert Ahrends and Radana Brumarov{\'a} and David Friedeck{\'y} and Gabriel Vivo-Truyols and Pavel {\v S}krha and Jan {\v S}krha and Radek Ku{\v c}era and Bohuslav Melichar and Gerhard Liebisch and Ralph Burkhardt and Wenk, {Markus R.} and Amaury Cazenave-Gassiot and Petr Kar{\'a}sek and Ivo Novotn{\'y} and Krist{\'i}na Greplov{\'a} and Roman Hrstka and Michal Hol{\v c}apek",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

doi = "10.1038/s41467-021-27765-9",

language = "English",

volume = "13",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Research",

number = "1",

}

Wolrab, D, Jirásko, R, Cífková, E, Höring, M, Mei, D, Chocholoušková, M, Peterka, O, Idkowiak, J, Hrnčiarová, T, Kuchař, L, Ahrends, R, Brumarová, R, Friedecký, D, Vivo-Truyols, G, Škrha, P, Škrha, J, Kučera, R, Melichar, B, Liebisch, G, Burkhardt, R, Wenk, MR, Cazenave-Gassiot, A, Karásek, P, Novotný, I, Greplová, K, Hrstka, R & Holčapek, M 2022, 'Lipidomic profiling of human serum enables detection of pancreatic cancer', Nature Communications, vol. 13, no. 1, 124. https://doi.org/10.1038/s41467-021-27765-9

TY - JOUR

T1 - Lipidomic profiling of human serum enables detection of pancreatic cancer

AU - Wolrab, Denise

AU - Jirásko, Robert

AU - Cífková, Eva

AU - Höring, Marcus

AU - Mei, Ding

AU - Chocholoušková, Michaela

AU - Peterka, Ondřej

AU - Idkowiak, Jakub

AU - Hrnčiarová, Tereza

AU - Kuchař, Ladislav

AU - Ahrends, Robert

AU - Brumarová, Radana

AU - Friedecký, David

AU - Vivo-Truyols, Gabriel

AU - Škrha, Pavel

AU - Škrha, Jan

AU - Kučera, Radek

AU - Melichar, Bohuslav

AU - Liebisch, Gerhard

AU - Burkhardt, Ralph

AU - Wenk, Markus R.

AU - Cazenave-Gassiot, Amaury

AU - Karásek, Petr

AU - Novotný, Ivo

AU - Greplová, Kristína

AU - Hrstka, Roman

AU - Holčapek, Michal

PY - 2022/12

Y1 - 2022/12

N2 - Pancreatic cancer has the worst prognosis among all cancers. Cancer screening of body fluids may improve the survival time prognosis of patients, who are often diagnosed too late at an incurable stage. Several studies report the dysregulation of lipid metabolism in tumor cells, suggesting that changes in the blood lipidome may accompany tumor growth. Here we show that the comprehensive mass spectrometric determination of a wide range of serum lipids reveals statistically significant differences between pancreatic cancer patients and healthy controls, as visualized by multivariate data analysis. Three phases of biomarker discovery research (discovery, qualification, and verification) are applied for 830 samples in total, which shows the dysregulation of some very long chain sphingomyelins, ceramides, and (lyso)phosphatidylcholines. The sensitivity and specificity to diagnose pancreatic cancer are over 90%, which outperforms CA 19-9, especially at an early stage, and is comparable to established diagnostic imaging methods. Furthermore, selected lipid species indicate a potential as prognostic biomarkers.

AB - Pancreatic cancer has the worst prognosis among all cancers. Cancer screening of body fluids may improve the survival time prognosis of patients, who are often diagnosed too late at an incurable stage. Several studies report the dysregulation of lipid metabolism in tumor cells, suggesting that changes in the blood lipidome may accompany tumor growth. Here we show that the comprehensive mass spectrometric determination of a wide range of serum lipids reveals statistically significant differences between pancreatic cancer patients and healthy controls, as visualized by multivariate data analysis. Three phases of biomarker discovery research (discovery, qualification, and verification) are applied for 830 samples in total, which shows the dysregulation of some very long chain sphingomyelins, ceramides, and (lyso)phosphatidylcholines. The sensitivity and specificity to diagnose pancreatic cancer are over 90%, which outperforms CA 19-9, especially at an early stage, and is comparable to established diagnostic imaging methods. Furthermore, selected lipid species indicate a potential as prognostic biomarkers.

UR - http://www.scopus.com/inward/record.url?scp=85122870459&partnerID=8YFLogxK

U2 - 10.1038/s41467-021-27765-9

DO - 10.1038/s41467-021-27765-9

M3 - Article

C2 - 35013261

AN - SCOPUS:85122870459

SN - 2041-1723

VL - 13

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 124

ER -

Lipidomic profiling of human serum enables detection of pancreatic cancer

Abstract

Access to Document

Other files and links

Fingerprint

Cite this